Oral Squamous Cell Carcinoma (OSCC)NCT07306546
Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer
A study testing Hydrogen Water Oral Care and Water Oral Care in people with Oral Squamous Cell Carcinoma (OSCC) and Postoperative Pain, run by Kaohsiung Medical University Chung-Ho Memorial Hospital at 1 site in Taiwan.
Trial summary
This randomized, double-blind, parallel-group controlled trial evaluates the effectiveness of hydrogen water oral care on acute oral inflammation, oral microbiota, and pain in patients with oral cancer who have undergone free flap reconstruction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oral Squamous Cell Carcinoma (OSCC), Postoperative Pain, Postoperative Oral Mucositis
- What is being tested?
- Hydrogen Water Oral Care and Water Oral Care
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteTaiwan
- Study dates
- 16 Dec 2025to 31 Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with oral cancer and undergoing microsurgical flap reconstruction.
- Age 18 years or older.
- Clear consciousness.
- Able to communicate without difficulty in Mandarin, Taiwanese, or in writing.
Who cannot join
- Abnormal salivary secretion function or severe xerostomia.
- Use of antibacterial mouthwash after surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
I-SHAN CHOU, +886-917-520-113, awoponn20@gmail.com
About this study
This randomized, double-blind, parallel-group controlled trial evaluates the effectiveness of hydrogen water oral care on acute oral inflammation, oral microbiota, and pain in patients with oral cancer who have undergone free flap reconstruction. After postoperative transfer from the intensive care unit to the plastic surgery ward, eligible patients who provide written informed consent are randomly assigned in a 1:1 ratio to receive oral care with either hydrogen water or boiled drinking water for 7 days. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention.
Read the detailed description
The research team explains the study purpose, intervention, possible risks, and participant rights to the participant (and/or legally authorized representative) in person and provides written information. After questions are answered and the informed consent form is signed, the participant is enrolled and randomly assigned by a computer-generated randomization table in a 1:1 ratio to the experimental group (hydrogen water oral care, n = 18) or the control group (boiled water oral care, n = 18).
The hydrogen water is produced on site by the research team using a nano hydrogen water machine (electrolytic reduction, nano micro-bubbles), with an average concentration of 1.1 mg/L, an oxidation-reduction potential of about -550 mV, and a hydrogen concentration shown to remain stable for 12 hours. The principal investigator prepares the hydrogen water twice a day. The hydrogen water and the boiled water are dispensed into bottles labeled only with the date and time, and are received and distributed by the research team nurse.
Oral condition is assessed with the Oral Assessment Guide (OAG; 8 items: voice, swallowing, lips, tongue, saliva, mucous membranes, gingiva, and teeth or dentures; each scored 1-3; total score 8-24), and the frequency of oral care is based on the OAG score: 8, once per shift; 9-10, every 4 hours; 11-24, every 2 hours. The first oral care is performed by the ward nurse according to ward routine, who also teaches the primary caregiver the correct procedure; after the caregiver can perform it proficiently, subsequent oral care is performed daily by the primary caregiver according to the schedule. The research team nurse checks the procedure daily and provides guidance and correction when needed. Oral care is performed with a sterile sponge toothbrush dipped in the assigned solution, gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, avoiding mechanical irritation, for 7 days. The control group uses boiled water in the same manner and at the same frequency, so that only the liquid differs between groups. The research team records the implementation and the patient's oral reactions daily. Both groups receive the same postoperative care and health education in the plastic surgery ward.
Saliva samples are collected on the day of transfer from the intensive care unit to the plastic surgery ward, immediately after group allocation (T0), and on Day 3 (T1) and Day 7 (T2) of the intervention. All saliva samples are collected in the morning, 30 minutes after oral care, by natural absorption with a syringe or a cotton roll placed in the mouth; participants do not eat, drink, or brush their teeth for 30 minutes before collection. At least 2 mL of saliva is collected in a sterile centrifuge tube and frozen within 30 minutes. IL-1β, IL-6, TNF-α, and IL-10 are quantified with LEGENDplex, and the oral microbiota is analyzed by 16S rRNA gene region analysis. Pain is assessed once daily with the Brief Pain Inventory-Taiwan (BPI-T).
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Postoperative Pain, Postoperative Oral Mucositis, Free Flap Reconstruction, Oral Cancer
- Being tested
- Hydrogen Water Oral Care, Water Oral Care
- Keywords
- Hydrogen water, Oral cancer, Free flap reconstruction, Pain assessment, Salivary Biomarkers
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck, Pain, Postoperative, Mouth Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hydrogen Water Oral CareOther
Oral care is performed with a sterile sponge toothbrush dipped in hydrogen water (average concentration 1.1 mg/L), gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, avoiding mechanical irritation, for 7 days. The hydrogen water is prepared on site twice a day with a nano hydrogen water machine.
Water Oral CareOther
Oral care is performed in the same manner and at the same frequency as the experimental group, with a sterile sponge toothbrush dipped in boiled water, gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, for 7 days. Only the liquid differs between the two groups.
| Study group | Role | What they receive |
|---|---|---|
| Hydrogen Water Oral Care Group | Experimental | Participants receive oral care with hydrogen water (dissolved hydrogen 1.1 mg/L, stability of at least 12 hours) for 7 days. The frequency of oral care is determined by the Oral Assessment Guide score. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention. Receives: Other: Hydrogen Water Oral Care |
| Water Oral Care Group | Placebo comparator | Participants receive oral care with boiled drinking water using the same procedures, frequency, and schedule as the experimental group for 7 days. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention. Receives: Other: Water Oral Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary IL-1β concentration
Salivary IL-1β concentration (pg/mL), quantified with LEGENDplex.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary IL-6 concentration
Salivary IL-6 concentration (pg/mL), quantified with LEGENDplex.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary TNF-α concentration
Salivary TNF-α concentration (pg/mL), quantified with LEGENDplex.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary IL-10 concentration
Salivary IL-10 concentration (pg/mL), quantified with LEGENDplex.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Secondary outcomes (3)
Oral microbiota diversity: Shannon index
Shannon diversity index of the salivary microbiota, based on 16S rRNA gene region analysis.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Oral microbiota diversity: Chao1 index
Chao1 richness index of the salivary microbiota, based on 16S rRNA gene region analysis.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Pain score measured by the Brief Pain Inventory-Taiwan (BPI-T)
Pain severity is measured with the BPI-T, rated on a 0-10 numeric scale (0 = no pain, 10 = pain as bad as you can imagine). Higher scores indicate more severe pain.
Measured: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start16 Dec 2025
- Primary completion31 Oct 2027 (estimated)
- Study completion31 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Squamous Cell Carcinoma (OSCC)Studies of the same condition, open and under way.
- More trials run by Kaohsiung Medical University Chung-Ho Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- I-SHAN CHOU, MS, Principal investigator, Kaohsiung Medical University Chung-Ho Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07306546
- Sponsor's protocol ID
- KMUHIRB-F(II)-20250332
- Status last verified
- Oct 2026
- First submitted
- 7 Dec 2025
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer
- ClinicalTrials.gov ID
- NCT07306546
- Acronym / sponsor ID
- KMUHIRB-F(II)-20250332
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Postoperative Pain, Postoperative Oral Mucositis, Free Flap Reconstruction, Oral Cancer
- Keywords
- Hydrogen water, Oral cancer, Free flap reconstruction, Pain assessment, Salivary Biomarkers
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Kaohsiung Medical University Chung-Ho Memorial HospitalUniversity, hospital or other
- Study start
- 16 Dec 2025 (actual)
- Primary completion
- 31 Oct 2027 (estimated)
- Study completion
- 31 Oct 2027 (estimated)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, parallel-group controlled trial evaluates the effectiveness of hydrogen water oral care on acute oral inflammation, oral microbiota, and pain in patients with oral cancer who have undergone free flap reconstruction. After postoperative transfer from the intensive care unit to the plastic surgery ward, eligible patients who provide written informed consent are randomly assigned in a 1:1 ratio to receive oral care with either hydrogen water or boiled drinking water for 7 days. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention.
Detailed description
The research team explains the study purpose, intervention, possible risks, and participant rights to the participant (and/or legally authorized representative) in person and provides written information. After questions are answered and the informed consent form is signed, the participant is enrolled and randomly assigned by a computer-generated randomization table in a 1:1 ratio to the experimental group (hydrogen water oral care, n = 18) or the control group (boiled water oral care, n = 18).
The hydrogen water is produced on site by the research team using a nano hydrogen water machine (electrolytic reduction, nano micro-bubbles), with an average concentration of 1.1 mg/L, an oxidation-reduction potential of about -550 mV, and a hydrogen concentration shown to remain stable for 12 hours. The principal investigator prepares the hydrogen water twice a day. The hydrogen water and the boiled water are dispensed into bottles labeled only with the date and time, and are received and distributed by the research team nurse.
Oral condition is assessed with the Oral Assessment Guide (OAG; 8 items: voice, swallowing, lips, tongue, saliva, mucous membranes, gingiva, and teeth or dentures; each scored 1-3; total score 8-24), and the frequency of oral care is based on the OAG score: 8, once per shift; 9-10, every 4 hours; 11-24, every 2 hours. The first oral care is performed by the ward nurse according to ward routine, who also teaches the primary caregiver the correct procedure; after the caregiver can perform it proficiently, subsequent oral care is performed daily by the primary caregiver according to the schedule. The research team nurse checks the procedure daily and provides guidance and correction when needed. Oral care is performed with a sterile sponge toothbrush dipped in the assigned solution, gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, avoiding mechanical irritation, for 7 days. The control group uses boiled water in the same manner and at the same frequency, so that only the liquid differs between groups. The research team records the implementation and the patient's oral reactions daily. Both groups receive the same postoperative care and health education in the plastic surgery ward.
Saliva samples are collected on the day of transfer from the intensive care unit to the plastic surgery ward, immediately after group allocation (T0), and on Day 3 (T1) and Day 7 (T2) of the intervention. All saliva samples are collected in the morning, 30 minutes after oral care, by natural absorption with a syringe or a cotton roll placed in the mouth; participants do not eat, drink, or brush their teeth for 30 minutes before collection. At least 2 mL of saliva is collected in a sterile centrifuge tube and frozen within 30 minutes. IL-1β, IL-6, TNF-α, and IL-10 are quantified with LEGENDplex, and the oral microbiota is analyzed by 16S rRNA gene region analysis. Pain is assessed once daily with the Brief Pain Inventory-Taiwan (BPI-T).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hydrogen Water Oral Care Group | Experimental | Other: Hydrogen Water Oral CareParticipants receive oral care with hydrogen water (dissolved hydrogen 1.1 mg/L, stability of at least 12 hours) for 7 days. The frequency of oral care is determined by the Oral Assessment Guide score. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention. |
| Water Oral Care Group | Placebo comparator | Other: Water Oral CareParticipants receive oral care with boiled drinking water using the same procedures, frequency, and schedule as the experimental group for 7 days. Saliva samples and pain assessments are collected at baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosed with oral cancer and undergoing microsurgical flap reconstruction.
- Age 18 years or older.
- Clear consciousness.
- Able to communicate without difficulty in Mandarin, Taiwanese, or in writing.
Key exclusion criteria (2 listed)
- Abnormal salivary secretion function or severe xerostomia.
- Use of antibacterial mouthwash after surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hydrogen Water Oral CareOral care is performed with a sterile sponge toothbrush dipped in hydrogen water (average concentration 1.1 mg/L), gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, avoiding mechanical irritation, for 7 days. The hydrogen water is prepared on site twice a day with a nano hydrogen water machine. | Other | Hydrogen Water Oral Care Group |
| Water Oral CareOral care is performed in the same manner and at the same frequency as the experimental group, with a sterile sponge toothbrush dipped in boiled water, gently brushing the oral mucosa, the upper and lower jaws, and the tongue surface, for 7 days. Only the liquid differs between the two groups. | Other | Water Oral Care Group |
Primary outcome
Salivary IL-1β concentration
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary IL-1β concentration (pg/mL), quantified with LEGENDplex.
Salivary IL-6 concentration
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary IL-6 concentration (pg/mL), quantified with LEGENDplex.
Salivary TNF-α concentration
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary TNF-α concentration (pg/mL), quantified with LEGENDplex.
Salivary IL-10 concentration
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Salivary IL-10 concentration (pg/mL), quantified with LEGENDplex.
3 secondary outcomes
Oral microbiota diversity: Shannon index
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Oral microbiota diversity: Chao1 index
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Pain score measured by the Brief Pain Inventory-Taiwan (BPI-T)
Time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Oral Squamous Cell Carcinoma (OSCC)
Active, not recruitingObservational study
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
HNSCC, OSCC
Active, not recruitingObservational study
Comparison of TLC (Total Leucocyte Count), Neutrophils and Monocytes in Oral Squamous Cell Carcinoma and Pre-malignant Disorders
Oral Squamous Cell Carcinoma (OSCC), Premalignant Lesion
RecruitingPhase 2
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
Head and Neck Cancer
Not yet recruitingPhase 2
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Recruiting
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
Oral Cancer, Lymph Node Metastasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
I-SHAN CHOU, MS principal investigator
Kaohsiung Medical University Chung-Ho Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hydrogen Water Oral Care and Water Oral Care in people with Oral Squamous Cell Carcinoma (OSCC) and Postoperative Pain, run by Kaohsiung Medical University Chung-Ho Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact I-SHAN CHOU, MS (+886-917-520-113, awoponn20@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary IL-1β concentration (time frame: Baseline (T0), Day 3 (T1), and Day 7 (T2) of the intervention). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.